Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
BOSTON, June 23, 2021 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology…
Month: June 2021
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Biosimulation Software for Evaluating Regulatory Submissions
The PMDA enters 8th consecutive year of using Certara’s biosimulation software PRINCETON, N.J., June 23,…
Neuronetics Set to Join Russell 2000® Index
MALVERN, Pa., June 23, 2021 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical…
GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association
Study highlights the clinical performance of NIS4® technology in diagnosing at-risk NASH in patients with…
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee
FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS)…
Pacific Biosciences and Rady Children’s Institute for Genomic Medicine Announce its First Research Collaboration for Whole Genome Sequencing
HiFi Sequencing will be used on a cohort of rare disease cases with the aim…
AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical…
DEINOVE- Adoption of all the ordinary resolutions at the Shareholders’ Meeting of June 21, 2021
DEINOVE- Adoption of all the ordinary resolutions at the Shareholders’ Meeting of June 21, 2021…
Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021
For information Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented…
Valneva Announces Successful Outcome of its AGM
Saint–Herblain (France), June 23, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty…
HUTCHMED Announces Pricing of Global Offering
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 23, 2021 (GLOBE NEWSWIRE) —…
Axiom Presents “Case Study for Achieving Full Data Capture in a Pivotal Medical Device Study” at Clinical Trials for Medical Devices Virtual Conference
TORONTO, June 23, 2021 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), premier provider of unified…
Tauriga Sciences, Inc. Appoints Colorado-based Orthopedic Surgeon, Dr. Craig Loucks, as Member of the Company’s Advisory Board
06_23 PR Image Composite of Alternate Blister Pack Designs (25mg CBD & CBG Infused) NEW…
Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11
— Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter…
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma
NEW YORK, June 23, 2021 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
Cybin to Present at the Life Sciences Investor Forum on June 24th
TORONTO, June 23, 2021 (GLOBE NEWSWIRE) — Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a…
Revolo Biotherapeutics Announces US FDA Approval of IND Application for Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis
NEW ORLEANS and LONDON, June 23, 2021 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio” or…
SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)
BREXAFEMME® (ibrexafungerp tablets), for oral use A novel oral antifungal approved for the treatment of…
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of…